Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.

doi:10.1007/s00125-008-1108-7

Skip navigation

Log in or Sign up
Set your institution here

Results
This Paper

Journals
Bookmarks

To show you the PDF, we need your affiliation

(Don't worry, you'll only have to do this once)

Affiliation:

Cancel

Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.

H H Boon, M M Bosselaar, S F E SF Praet, E E EE Blaak, W H M WH Saris, A J M AJ Wagenmakers, S L SL McGee, C J CJ Tack, P P Smits, M M Hargreaves and L J C LJ van Loon Diabetologia 51(10):1893-900 (2008) PMID 18709353

The 5'-AMP-activated protein kinase (AMPK) pathway is intact in type 2 diabetic patients and is seen as a target for diabetes treatment. In this study, we aimed to assess the impact of the AMPK activator 5-aminoimidazole-4-carboxamide riboside (AICAR) on both glucose and fatty acid metabolism in vivo in type 2 diabetic patients.

DOI: 10.1007/s00125-008-1108-7
Version: za2963e q8za9 q8zba q8zcc q8zd0 q8ze6 q8zf1 q8zga

Advanced search Close

Limits Clear all Close

To show you the PDF, we need your affiliation

Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.

paper

citation

Thanks for joining pubget!

Sign up for free.

Log in to Pubget.

Advanced search Close

Limits Clear all Close

To show you the PDF, we need your affiliation

Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.

paper

citation